# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-26-048922
Filing Date
2026-07-21
Accepted
2026-07-21 07:06:05
Documents
8
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | telix-6kforq22026tradingup.htm | 6-K | 21420
2 | EX-99.1 | a20260721telixq2revenueu.htm | EX-99.1 | 23314
3 |  | a20260721telixq2revenueu001.jpg | GRAPHIC | 223227
4 |  | a20260721telixq2revenueu002.jpg | GRAPHIC | 269653
5 |  | a20260721telixq2revenueu003.jpg | GRAPHIC | 253680
6 |  | a20260721telixq2revenueu004.jpg | GRAPHIC | 233823
7 |  | a20260721telixq2revenueu005.jpg | GRAPHIC | 218743
8 |  | a20260721telixq2revenueu006.jpg | GRAPHIC | 166553
| Complete submission text file | 0001628280-26-048922.txt |  | 1927264

Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855
Telix Pharmaceuticals Ltd (Filer) CIK: 0002007191 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 261188143
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)